Time to treatment withdrawal · people with epilepsy
VGB showed no clear difference in time to treatment withdrawal compared with CBZ monotherapy (low certainty).
1 finding from 1 review
Time to achieve 6‐month remission after the first 6 weeks of dose stabilisation from randomisation · people with epilepsy
It is very uncertain whether VGB changes time to achieve 6‐month remission after the first 6 weeks of dose… compared with CBZ monotherapy (very low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · people with epilepsy
VGB may leads to higher time to first seizure after randomisation compared with CBZ monotherapy (low certainty).
1 finding from 1 review
Adverse events Visual field defects · people with epilepsy
It is very uncertain whether VGB changes adverse events Visual field defects compared with CBZ monotherapy (very low certainty).
1 finding from 1 review
ACR 50 response of DMARDs naive patients Number of responders · patients with rheumatoid arthritis
MTX combination showed no clear difference in ACR 50 response of DMARDs naive patients Number of responders compared with MTX monotherapy (low certainty).
1 finding from 1 review
ACR 50 response of MTX inadequate responders number of responders · patients with rheumatoid arthritis
MTX combination probably leads to higher ACR 50 response of MTX inadequate responders number of responders compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
ACR 50 response of non‐MTX DMARDs inadequate responders number of responders · patients with rheumatoid arthritis
MTX combination showed no clear difference in ACR 50 response of non‐MTX DMARDs inadequate responders number of… compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
Withdrawal due to lack of efficacy or toxicity of DMARDs naive patients number of withdrawals · patients with rheumatoid arthritis
MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of DMARDs naive… compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
Withdrawal due to lack of efficacy or toxicity of MTX inadequate responders number of withdrawals · patients with rheumatoid arthritis
MTX combination showed no clear difference in withdrawal due to lack of efficacy or toxicity of MTX inadequate… compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
Withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs inadequate responders number of withdrawals · patients with rheumatoid arthritis
It is very uncertain whether MTX combination changes withdrawal due to lack of efficacy or toxicity of non‐MTX DMARDs… compared with MTX monotherapy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis
It is very uncertain whether MTX combination changes withdrawal due to adverse reactions (Pooled across regimens) number… compared with MTX monotherapy (very low certainty).
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Varenicline leads to higher smoking abstinence at longest compared with nicotine replacement therapy monotherapy (high certainty).
1 finding from 1 review
SAEs · people who smoke
Varenicline may leads to lower SAEs compared with nicotine replacement therapy monotherapy (low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
1 finding from 1 review
Cardiac SAEs · people who smoke
1 finding from 1 review
All‐cause mortality at 1 year · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Cancer‐related mortality at maximal · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found